{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:59:14Z","timestamp":1781193554283,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82474096"],"award-info":[{"award-number":["82474096"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"DOI":"10.1007\/s00011-026-02262-1","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T03:36:44Z","timestamp":1779766604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PCSK9 orchestrates the antigen presentation\u2013endothelial barrier axis to potentiate immune exclusion in colorectal cancer"],"prefix":"10.1007","volume":"75","author":[{"given":"Gang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengyaran","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengyi","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Decai","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"3","key":"2262_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834. Epub 2024 Apr 4. PMID: 38572751.","journal-title":"CA Cancer J Clin"},{"key":"2262_CR2","doi-asserted-by":"publisher","first-page":"1403533","DOI":"10.3389\/fimmu.2024.1403533","volume":"15","author":"S Yan","year":"2024","unstructured":"Yan S, Wang W, Feng Z, Xue J, Liang W, Wu X, et al. Immune checkpoint inhibitors in colorectal cancer: limitation and challenges. Front Immunol. 2024;15:1403533. https:\/\/doi.org\/10.3389\/fimmu.2024.1403533.","journal-title":"Front Immunol"},{"issue":"3","key":"2262_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","volume":"36","author":"T Andr\u00e9","year":"2025","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, et al. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. Ann Oncol. 2025;36(3):277\u201384. https:\/\/doi.org\/10.1016\/j.annonc.2024.11.012.","journal-title":"Ann Oncol"},{"issue":"12","key":"2262_CR4","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1002\/ijc.35347","volume":"156","author":"A Haslam","year":"2025","unstructured":"Haslam A, Olivier T, Prasad V. How many people in the US are eligible for and respond to checkpoint inhibitors: an empirical analysis. Int J Cancer. 2025;156(12):2352\u20139. https:\/\/doi.org\/10.1002\/ijc.35347.","journal-title":"Int J Cancer"},{"issue":"8","key":"2262_CR5","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186(8):1652\u201369. https:\/\/doi.org\/10.1016\/j.cell.2023.03.006.","journal-title":"Cell"},{"key":"2262_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01211-z","author":"AU Kabir","year":"2025","unstructured":"Kabir AU, Subramanian M, Kwon Y, et al. Linking tumour angiogenesis and tumour immunity. Nat Rev Immunol. 2025. https:\/\/doi.org\/10.1038\/s41577-025-01211-z.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2262_CR7","doi-asserted-by":"publisher","first-page":"e006401","DOI":"10.1136\/jitc-2022-006401","volume":"11","author":"MM Melssen","year":"2023","unstructured":"Melssen MM, Sheybani ND, Leick KM, Slingluff CL Jr. Barriers to immune cell infiltration in tumors. J Immunother Cancer. 2023;11(4):e006401. https:\/\/doi.org\/10.1136\/jitc-2022-006401.","journal-title":"J Immunother Cancer"},{"key":"2262_CR8","doi-asserted-by":"publisher","first-page":"1291530","DOI":"10.3389\/fimmu.2023.1291530","volume":"14","author":"C Qian","year":"2023","unstructured":"Qian C, Liu C, Liu W, Zhou R, Zhao L. Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy. Front Immunol. 2023;14:1291530. https:\/\/doi.org\/10.3389\/fimmu.2023.1291530.","journal-title":"Front Immunol"},{"key":"2262_CR9","doi-asserted-by":"publisher","first-page":"7383","DOI":"10.2147\/IJN.S467222","volume":"19","author":"Z Jiang","year":"2024","unstructured":"Jiang Z, Fang Z, Hong D, Wang X. Cancer immunotherapy with \u201cvascular-immune\u201d crosstalk as entry point: associated mechanisms, therapeutic drugs and nano-delivery systems. Int J Nanomedicine. 2024;19:7383\u201398. https:\/\/doi.org\/10.2147\/IJN.S467222.","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"2262_CR10","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.molmed.2023.11.002","volume":"30","author":"AH Cleveland","year":"2024","unstructured":"Cleveland AH, Fan Y. Reprogramming endothelial cells to empower cancer immunotherapy. Trends Mol Med. 2024;30(2):126\u201335. https:\/\/doi.org\/10.1016\/j.molmed.2023.11.002. Epub 2023 Nov 30. PMID: 38040601; PMCID: PMC10922198.","journal-title":"Trends Mol Med"},{"issue":"3","key":"2262_CR11","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1210\/endrev\/bnab035","volume":"43","author":"NG Seidah","year":"2022","unstructured":"Seidah NG, Prat A. The multifaceted biology of PCSK9. Endocr Rev. 2022;43(3):558\u201382. https:\/\/doi.org\/10.1210\/endrev\/bnab035.","journal-title":"Endocr Rev"},{"key":"2262_CR12","doi-asserted-by":"publisher","first-page":"764038","DOI":"10.3389\/fcvm.2021.764038","volume":"8","author":"XD Xia","year":"2021","unstructured":"Xia XD, Peng ZS, Gu HM, Wang M, Wang GQ, Zhang DW. Regulation of PCSK9 expression and function: mechanisms and therapeutic implications. Front Cardiovasc Med. 2021;8:764038. https:\/\/doi.org\/10.3389\/fcvm.2021.764038.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"2262_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41392-023-01690-3","volume":"9","author":"X Bao","year":"2024","unstructured":"Bao X, Liang Y, Chang H, Cai T, Feng B, Gordon K, et al. Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside. Signal Transduct Target Ther. 2024;9(1):13. https:\/\/doi.org\/10.1038\/s41392-023-01690-3. PMID: 38185721; PMCID: PMC10772138.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2262_CR14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12944-024-02151-8","volume":"23","author":"M Mahjoubin-Tehran","year":"2024","unstructured":"Mahjoubin-Tehran M, Rezaei S, Santos RD, Jamialahmadi T, Almahmeed W, Sahebkar A. Targeting PCSK9 as a key player in lipid metabolism: exploiting the therapeutic and biosensing potential of aptamers. Lipids Health Dis. 2024;23(1):156. https:\/\/doi.org\/10.1186\/s12944-024-02151-8. PMID: 38796450; PMCID: PMC11128129.","journal-title":"Lipids Health Dis"},{"issue":"1","key":"2262_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s40364-024-00712-8","volume":"12","author":"Y Wang","year":"2024","unstructured":"Wang Y, Fang X, Liu J, Lv X, Lu K, Lu Y, et al. PCSK9 in T-cell function and the immune response. Biomark Res. 2024;12(1):163. https:\/\/doi.org\/10.1186\/s40364-024-00712-8. PMID: 39736777; PMCID: PMC11687167.","journal-title":"Biomark Res"},{"key":"2262_CR16","doi-asserted-by":"publisher","first-page":"1308070","DOI":"10.3389\/fimmu.2024.1308070","volume":"15","author":"Y Xu","year":"2024","unstructured":"Xu Y, Shao B, Zhang Y. The significance of targeting lysosomes in cancer immunotherapy. Front Immunol. 2024;15:1308070. https:\/\/doi.org\/10.3389\/fimmu.2024.1308070. PMID: 38370407; PMCID: PMC10869645.","journal-title":"Front Immunol"},{"issue":"5","key":"2262_CR17","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.3390\/cancers15051397","volume":"15","author":"V Quagliariello","year":"2023","unstructured":"Quagliariello V, Bisceglia I, Berretta M, Iovine M, Canale ML, Maurea C, et al. PCSK9 inhibitors in cancer patients treated with immune-checkpoint inhibitors to reduce cardiovascular events: New frontiers in cardioncology. Cancers (Basel). 2023;15(5):1397. https:\/\/doi.org\/10.3390\/cancers15051397. PMID: 36900189; PMCID: PMC10000232.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"2262_CR18","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/s44161-022-00172-z","volume":"1","author":"Y Jin","year":"2022","unstructured":"Jin Y, Ding Y, Richards M, Kaakinen M, Giese W, Baumann E, et al. Tyrosine-protein kinase Yes controls endothelial junctional plasticity and barrier integrity by regulating VE-cadherin phosphorylation and endocytosis. Nat Cardiovasc Res. 2022;1(12):1156\u201373. https:\/\/doi.org\/10.1038\/s44161-022-00172-z. PMID: 37936984; PMCID: PMC7615285.","journal-title":"Nat Cardiovasc Res"},{"issue":"9","key":"2262_CR19","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1038\/s44319-024-00221-7","volume":"25","author":"M Wilkens","year":"2024","unstructured":"Wilkens M, Holtermann L, Stahl AK, Stegmeyer RI, Nottebaum AF, Vestweber D. Ubiquitination of VE-cadherin regulates inflammation-induced vascular permeability in vivo. EMBO Rep. 2024;25(9):4013\u201332. https:\/\/doi.org\/10.1038\/s44319-024-00221-7. Epub 2024 Aug 7. PMID: 39112792; PMCID: PMC11387630.","journal-title":"EMBO Rep"},{"issue":"1","key":"2262_CR20","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1038\/s41467-023-42225-2","volume":"14","author":"C Tiruppathi","year":"2023","unstructured":"Tiruppathi C, Wang DM, Ansari MO, Bano S, Tsukasaki Y, Mukhopadhyay A, et al. Ubiquitin ligase CHFR mediated degradation of VE-cadherin through ubiquitylation disrupts endothelial adherens junctions. Nat Commun. 2023;14(1):6582. https:\/\/doi.org\/10.1038\/s41467-023-42225-2. PMID: 37852964; PMCID: PMC10584835.","journal-title":"Nat Commun"},{"key":"2262_CR21","doi-asserted-by":"publisher","first-page":"1234104","DOI":"10.3389\/fphys.2023.1234104","volume":"14","author":"W Nan","year":"2023","unstructured":"Nan W, He Y, Wang S, Zhang Y. Molecular mechanism of VE-cadherin in regulating endothelial cell behaviour during angiogenesis. Front Physiol. 2023;14:1234104. https:\/\/doi.org\/10.3389\/fphys.2023.1234104. PMID: 37601629; PMCID: PMC10433914.","journal-title":"Front Physiol"},{"issue":"5","key":"2262_CR22","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.7150\/ijbs.78248","volume":"19","author":"R Wang","year":"2023","unstructured":"Wang R, Ni C, Lou X, Zhang L, Wang L, Yao X, et al. IFN\u03b3 blockade in capillary leak site improves tumour chemotherapy by inhibiting lactate-induced endocytosis of vascular endothelial-cadherins. Int J Biol Sci. 2023;19(5):1490\u2013508. https:\/\/doi.org\/10.7150\/ijbs.78248. PMID: 37056922; PMCID: PMC10086745.","journal-title":"Int J Biol Sci"},{"key":"2262_CR23","doi-asserted-by":"publisher","first-page":"156208","DOI":"10.1016\/j.cyto.2023.156208","volume":"166","author":"CT Ng","year":"2023","unstructured":"Ng CT, Fong LY, Abdullah MNH. Interferon-gamma (IFN-\u03b3): reviewing its mechanisms and signaling pathways on the regulation of endothelial barrier function. Cytokine. 2023;166:156208. https:\/\/doi.org\/10.1016\/j.cyto.2023.156208. Epub 2023 Apr 21. PMID: 37088004.","journal-title":"Cytokine"},{"issue":"1","key":"2262_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00018-025-05753-2","volume":"82","author":"L Holtermann","year":"2025","unstructured":"Holtermann L, Rivera-Galdos R, Nottebaum AF, Wessel F, Ipe U, Vestweber D. Distinct VE-cadherin serine and tyrosine phosphorylation sites and their role for inflammation-induced vascular permeability in vivo. Cell Mol Life Sci. 2025;82(1):223. https:\/\/doi.org\/10.1007\/s00018-025-05753-2. PMID: 40471304; PMCID: PMC12141182.","journal-title":"Cell Mol Life Sci"},{"key":"2262_CR25","doi-asserted-by":"publisher","first-page":"1551322","DOI":"10.3389\/fimmu.2025.1551322","volume":"16","author":"Z Cai","year":"2025","unstructured":"Cai Z, Meng K, Yu T, Xi Y, Yuan Z, Wang X, et al. IFN-\u03b3-mediated suppression of ANGPT2-Tie2 in endothelial cells facilitates tumor vascular normalization during immunotherapy. Front Immunol. 2025;16:1551322. https:\/\/doi.org\/10.3389\/fimmu.2025.1551322. PMID: 40370455; PMCID: PMC12075545.","journal-title":"Front Immunol"},{"issue":"3","key":"2262_CR26","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ccell.2023.02.002","volume":"41","author":"G Vella","year":"2023","unstructured":"Vella G, Hua Y, Bergers G. High endothelial venules in cancer: regulation, function, and therapeutic implication. Cancer Cell. 2023;41(3):527\u201345. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.002. Epub 2023 Feb 23. PMID: 36827979.","journal-title":"Cancer Cell"},{"issue":"11","key":"2262_CR27","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1038\/s12276-023-01114-w","volume":"55","author":"Y Choi","year":"2023","unstructured":"Choi Y, Jung K. Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy. Exp Mol Med. 2023;55(11):2308\u201319. https:\/\/doi.org\/10.1038\/s12276-023-01114-w. Epub 2023 Nov 1. PMID: 37907742; PMCID: PMC10689787.","journal-title":"Exp Mol Med"},{"issue":"1","key":"2262_CR28","doi-asserted-by":"publisher","first-page":"2472070","DOI":"10.1080\/17590914.2025.2472070","volume":"17","author":"TN Trevino","year":"2025","unstructured":"Trevino TN, Almousawi AA, Martins-Goncalves R, Ochoa-Raya A, Robinson KF, Abad GL, et al. A brain endothelial cell Caveolin-1\/CXCL10 axis promotes T cell transcellular migration across the blood-brain barrier. ASN Neuro. 2025;17(1):2472070. https:\/\/doi.org\/10.1080\/17590914.2025.2472070. Epub 2025 Mar 10. PMID: 40063988; PMCID: PMC12047051.","journal-title":"ASN Neuro"},{"key":"2262_CR29","doi-asserted-by":"publisher","first-page":"1198972","DOI":"10.3389\/fimmu.2023.1198972","volume":"14","author":"J Tu","year":"2023","unstructured":"Tu J, Liang H, Li C, Huang Y, Wang Z, Chen X, et al. The application and research progress of anti-angiogenesis therapy in tumor immunotherapy. Front Immunol. 2023;14:1198972. https:\/\/doi.org\/10.3389\/fimmu.2023.1198972. PMID: 37334350; PMCID: PMC10272381.","journal-title":"Front Immunol"},{"key":"2262_CR30","doi-asserted-by":"publisher","first-page":"1487610","DOI":"10.3389\/fimmu.2024.1487610","volume":"15","author":"Q Xu","year":"2024","unstructured":"Xu Q, Shao D. Leveraging the synergy between anti-angiogenic therapy and immune checkpoint inhibitors to treat digestive system cancers. Front Immunol. 2024;15:1487610. https:\/\/doi.org\/10.3389\/fimmu.2024.1487610. PMID: 39691707; PMCID: PMC11649667.","journal-title":"Front Immunol"},{"issue":"9","key":"2262_CR31","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","volume":"82","author":"SS Virani","year":"2023","unstructured":"Writing Committee Members, Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: A report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines. J Am Coll Cardiol. 2023;82(9):833\u2013955. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.003. Epub 2023 Jul 20. Erratum in: J Am Coll Cardiol. 2023 Oct 31;82(18):1808. doi: 10.1016\/j.jacc.2023.09.794. Erratum in: J Am Coll Cardiol. 2024 Apr 30; 83(17): 1716. doi: 10.1016\/j.jacc.2024.03.399. PMID: 37480922.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"2262_CR32","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","volume":"146","author":"ML O'Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146(15):1109\u201319. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061620. Epub 2022 Aug 29. PMID: 36031810.","journal-title":"Circulation"},{"issue":"4","key":"2262_CR33","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/ehjcvp\/pvae025","volume":"10","author":"SG Goodman","year":"2024","unstructured":"Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation. Eur Heart J Cardiovasc Pharmacother. 2024;10(4):342\u201352. https:\/\/doi.org\/10.1093\/ehjcvp\/pvae025. PMID: 38658193; PMCID: PMC11249957.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"2","key":"2262_CR34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.trecan.2024.10.002","volume":"11","author":"S Sun","year":"2025","unstructured":"Sun S, Yang Z, Yao H, Zhang Z. A new enhancer for anti-PD-1\/PD-L1 immunotherapy: PCSK9 inhibition. Trends Cancer. 2025;11(2):84\u20137. https:\/\/doi.org\/10.1016\/j.trecan.2024.10.002. Epub 2024 Oct 24. PMID: 39455406.","journal-title":"Trends Cancer"},{"key":"2262_CR35","doi-asserted-by":"publisher","first-page":"1549276","DOI":"10.3389\/fimmu.2025.1549276","volume":"16","author":"S Shi","year":"2025","unstructured":"Shi S, Ou X, Liu C, Wen H, Ke J. Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment. Front Immunol. 2025;16:1549276. https:\/\/doi.org\/10.3389\/fimmu.2025.1549276. PMID: 39981236; PMCID: PMC11839635.","journal-title":"Front Immunol"},{"issue":"12","key":"2262_CR36","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.3390\/cancers17121977","volume":"17","author":"A Martin","year":"2025","unstructured":"Martin A, Gerovska D, Arauzo-Bravo MJ, Duarte Garc\u00eda-Escudero M, Garc\u00edaGarc\u00eda H, Ba\u00f1ares I, et al. Inhibition of PCSK9 attenuates liver endothelial cell activation induced by colorectal cancer stem cells during liver metastasis. Cancers (Basel). 2025;17(12):1977. https:\/\/doi.org\/10.3390\/cancers17121977. PMID: 40563628; PMCID: PMC12190733.","journal-title":"Cancers (Basel)"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02262-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-026-02262-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02262-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:08:35Z","timestamp":1781190515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-026-02262-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2262"],"URL":"https:\/\/doi.org\/10.1007\/s00011-026-02262-1","relation":{},"ISSN":["1420-908X"],"issn-type":[{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that this research was conducted without any commercial or financial relationships that could be interpreted as potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"120"}}